Gilead Acquires Polymerase Theta Program From Repare in $30M Strategic Deal

Repare Therapeutics Inc. (RPTX) has finalized an acquisition agreement with Gilead Sciences, Inc. (GILD) to transfer ownership of RP-3467, a synthetic lethality-targeted therapeutic candidate. The transaction structure includes a $25 million upfront payment upon closing and an additional $5 million contingent on successful technology transfer milestones, totaling $30 million in consideration.

Market Response and Shareholder Impact

The announcement triggered immediate market enthusiasm, with RPTX shares jumping 20.73% in pre-market trading to reach $2.62, marking a new 52-week high. This price action significantly surpasses the stock’s annual range of $0.89 to $2.30, reflecting investor confidence in the deal’s strategic value.

For Repare shareholders, the capital infusion carries particular significance given the company’s pending merger with Xeno Therapeutics. Based on current valuations, shareholders are projected to receive approximately US$2.20 per share upon transaction closure, with the Gilead payment strengthening the overall deal economics.

Technology Transfer and Clinical Development

RP-3467 represents a potent small-molecule inhibitor targeting polymerase theta (Pol θ), an enzyme whose dysfunction creates a synthetic lethal vulnerability in BRCA-mutant and genomically altered cancer cells. The polymerase theta copy and paste repair mechanisms make it an attractive oncology target.

Currently, the asset progresses through the POLAR Phase 1 clinical trial, which evaluates RP-3467 as a monotherapy and in combination with olaparib. The trial population encompasses patients with advanced ovarian, breast, prostate, and pancreatic malignancies, positioning the program within Gilead’s existing oncology portfolio.

Strategic Rationale and Portfolio Impact

This acquisition marks Repare’s third significant portfolio divestment during 2025, demonstrating the company’s success in monetizing its precision oncology pipeline. The transaction underscores Gilead’s sustained commitment to synthetic lethality-based therapeutic development and oncology expansion.

For Repare, the near-term liquidity from the upfront payment provides financial flexibility as it navigates the broader Xeno Therapeutics strategic transaction. CEO Steve Forte stated, “This transaction leverages Gilead’s established oncology research and development capabilities alongside RP-3467, positioning the program as a potential best-in-class polymerase theta ATPase inhibitor for the market.”

The deal illustrates the broader pharma industry trend of acquiring precision oncology assets targeting DNA repair pathways, with polymerase theta emerging as a validated therapeutic target in synthetic lethality strategies.